We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 4, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (MRK - Free Report) , Pfizer (PFE - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Amgen (AMGN - Free Report) and Bristol Myers Squibb (BMY - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecast
The fourth-quarter earnings season for the drug and biotech sector will be in full swing this week with many large drugmakers like — Merck, Pfizer, Eli Lilly and Co., Amgen and Bristol Myers Squibb — due to announce results. Johnson & Johnson and AbbVie have already reported with both beating estimates for both earnings and sales. French drugmaker Sanofi came out with disappointing fourth-quarter results as it missed estimates for both earnings and sales.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector, comprising pharma/biotech and generic companies, and medical device companies.
Per the Earnings Trends report, as of Jan 29, 12.3% of the companies in the Medical sector — representing 30.8% of the sector’s market capitalization — reported quarterly earnings. Of these, 85.7% beat on earnings, while 57.1% beat on revenues. Earnings increased 1.4% year over year, while revenues grew 6.6%. Overall, fourth-quarter earnings of the Medical sector are expected to increase 12.5% year over year, while revenues are likely to grow 8.6%.
Let’s see how things have shaped up for these companies ahead of their earnings announcements.
Merck
MRK’s performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 37.57%, on average. In the last reported quarter, the company delivered an earnings surprise of 4.67%.
The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $15.56 billion and $1.69 per share, respectively.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Merck’s top-line growth in the fourth quarter is likely to have been driven by blockbuster cancer drug Keytruda, like in several previous quarters, aided by additional indications and patient demand. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 4, before market open.
PFE’s performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 74.50%, on average. In the last reported quarter, the company delivered an earnings surprise of 65.62%.
PFE has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $17.50 billion and 48 cents per share, respectively.
Though sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined in the past few quarters, it seems that sales have stabilized somewhat. The company’s non-COVID operational revenues have been driving its top-line growth, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products like Nurtec, as well as those acquired from Seagen (December 2023). PFE is scheduled to report fourth-quarter and full-year 2024 results on Feb. 4, before the opening bell.
LLY’s performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters and missing the same on the remaining occasion. It delivered a four-quarter earnings surprise of 7.23%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 22.37%.
Lilly has an Earnings ESP of -2.08% and a Zacks Rank #3. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $13.48 billion and $5.15 per share, respectively.
In mid-January, Lilly lowered its sales guidance for full-year 2024 and announced disappointing preliminary sales numbers for the fourth quarter. Lilly expects revenues to be approximately $45.0 billion in full-year 2024, which falls short of its previous guidance range of $45.4 billion to $46.0 billion.
In the fourth quarter, revenues are expected to be approximately $13.5 billion, shy of the consensus estimate due to lower-than-expected sales of Mounjaro and Zepbound.
Higher demand and volume growth for LLY’s key growth drugs like Emgality, Olumiant, Retevmo, Taltz and Verzenio are likely to have provided top-line support in the fourth quarter, driven by increased demand trends. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 6, before market open.
AMGN’s performance has been strong, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 4.10%, on average. In the last reported quarter, the company delivered an earnings surprise of 9.20%.
AMGN has an Earnings ESP of +1.74% and a Zacks Rank #3, indicating a likely earnings beat this time around. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $8.86 billion and $5.03 per share, respectively.
Amgen’s product sales in the fourth quarter are expected to have been driven by strong volume growth of Evenity, Repatha, Prolia, Kyprolis and Blincyto, among others. However, prices of most products declined due to higher rebates to support expanded access. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 4, after market close.
BMY’s performance has been strong, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 15.54%, on average. In the last reported quarter, the company delivered an earnings surprise of 20.81%.
BMY has an Earnings ESP of +0.43% and a Zacks Rank #3, indicating a likely earnings beat this time around. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $11.56 billion and $1.46 per share, respectively.
Consistent label expansions in newer metastatic and adjuvant indications are likely to have maintained momentum for the blockbuster immuno-oncology drug Opdivo in the fourth quarter.
Total revenues in the fourth quarter are likely to have increased on the back of growth in product franchise sales. Its growth portfolio primarily comprises sales from immuno-oncology drugs like Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 6, before market open.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb
For Immediate Release
Chicago, IL – February 4, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (MRK - Free Report) , Pfizer (PFE - Free Report) , Eli Lilly and Co. (LLY - Free Report) , Amgen (AMGN - Free Report) and Bristol Myers Squibb (BMY - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecast
The fourth-quarter earnings season for the drug and biotech sector will be in full swing this week with many large drugmakers like — Merck, Pfizer, Eli Lilly and Co., Amgen and Bristol Myers Squibb — due to announce results. Johnson & Johnson and AbbVie have already reported with both beating estimates for both earnings and sales. French drugmaker Sanofi came out with disappointing fourth-quarter results as it missed estimates for both earnings and sales.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Per the Zacks classification, the pharma/biotech industry falls under the broader Medical sector, comprising pharma/biotech and generic companies, and medical device companies.
Per the Earnings Trends report, as of Jan 29, 12.3% of the companies in the Medical sector — representing 30.8% of the sector’s market capitalization — reported quarterly earnings. Of these, 85.7% beat on earnings, while 57.1% beat on revenues. Earnings increased 1.4% year over year, while revenues grew 6.6%. Overall, fourth-quarter earnings of the Medical sector are expected to increase 12.5% year over year, while revenues are likely to grow 8.6%.
Let’s see how things have shaped up for these companies ahead of their earnings announcements.
Merck
MRK’s performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 37.57%, on average. In the last reported quarter, the company delivered an earnings surprise of 4.67%.
Merck has an Earnings ESP of -2.98% and a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $15.56 billion and $1.69 per share, respectively.
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Merck’s top-line growth in the fourth quarter is likely to have been driven by blockbuster cancer drug Keytruda, like in several previous quarters, aided by additional indications and patient demand. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 4, before market open.
Merck & Co., Inc. price-eps-surprise | Merck & Co., Inc. Quote
Pfizer
PFE’s performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 74.50%, on average. In the last reported quarter, the company delivered an earnings surprise of 65.62%.
PFE has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $17.50 billion and 48 cents per share, respectively.
Though sales of Pfizer’s COVID products, Comirnaty and Paxlovid, declined in the past few quarters, it seems that sales have stabilized somewhat. The company’s non-COVID operational revenues have been driving its top-line growth, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products like Nurtec, as well as those acquired from Seagen (December 2023). PFE is scheduled to report fourth-quarter and full-year 2024 results on Feb. 4, before the opening bell.
Pfizer Inc. price-eps-surprise | Pfizer Inc. Quote
Eli Lilly and Company
LLY’s performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters and missing the same on the remaining occasion. It delivered a four-quarter earnings surprise of 7.23%, on average. In the last reported quarter, the company delivered a negative earnings surprise of 22.37%.
Lilly has an Earnings ESP of -2.08% and a Zacks Rank #3. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $13.48 billion and $5.15 per share, respectively.
In mid-January, Lilly lowered its sales guidance for full-year 2024 and announced disappointing preliminary sales numbers for the fourth quarter. Lilly expects revenues to be approximately $45.0 billion in full-year 2024, which falls short of its previous guidance range of $45.4 billion to $46.0 billion.
In the fourth quarter, revenues are expected to be approximately $13.5 billion, shy of the consensus estimate due to lower-than-expected sales of Mounjaro and Zepbound.
Higher demand and volume growth for LLY’s key growth drugs like Emgality, Olumiant, Retevmo, Taltz and Verzenio are likely to have provided top-line support in the fourth quarter, driven by increased demand trends. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 6, before market open.
Eli Lilly and Company price-eps-surprise | Eli Lilly and Company Quote
Amgen
AMGN’s performance has been strong, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 4.10%, on average. In the last reported quarter, the company delivered an earnings surprise of 9.20%.
AMGN has an Earnings ESP of +1.74% and a Zacks Rank #3, indicating a likely earnings beat this time around. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $8.86 billion and $5.03 per share, respectively.
Amgen’s product sales in the fourth quarter are expected to have been driven by strong volume growth of Evenity, Repatha, Prolia, Kyprolis and Blincyto, among others. However, prices of most products declined due to higher rebates to support expanded access. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 4, after market close.
Amgen Inc. price-eps-surprise | Amgen Inc. Quote
Bristol Myers Squibb
BMY’s performance has been strong, with earnings beating estimates in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 15.54%, on average. In the last reported quarter, the company delivered an earnings surprise of 20.81%.
BMY has an Earnings ESP of +0.43% and a Zacks Rank #3, indicating a likely earnings beat this time around. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $11.56 billion and $1.46 per share, respectively.
Consistent label expansions in newer metastatic and adjuvant indications are likely to have maintained momentum for the blockbuster immuno-oncology drug Opdivo in the fourth quarter.
Total revenues in the fourth quarter are likely to have increased on the back of growth in product franchise sales. Its growth portfolio primarily comprises sales from immuno-oncology drugs like Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. The company is scheduled to report fourth-quarter and full-year 2024 results on Feb. 6, before market open.
Bristol Myers Squibb Company price-eps-surprise | Bristol Myers Squibb Company Quote
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.